English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

he outcome of patients with acute myocardial infarction (MI) has been substantially improved by the introduction of reperfusion therapy and its continuous refinement. Current reperfusion methodology salvages more than 50% of the ischemic myocardium from infarction in approximately half of acute MI patients without cardiogenic shock. 1 However, in 25% of acute MI patients, myocardial salvage by reperfusion is minimal, leaving the infarct larger than 20% of the ventricular mass.1 It is this subgroup of patients with large infarcts that particularly needs potent therapy for preventing subsequent heart failure.

Are Treatment Effects of ACEI and ARB in Post-MI Patients Homogeneous?